AO-176 is an anti-CD47 monoclonal antibody currently being developed for patients with multiple myeloma and select solid tumors. Arch Oncology is evaluating this therapy both as a monotherapy and in combination with standard therapies.

SparkCures ID 391
Developed By Arch Oncology
Generic Name AO-176
Treatment Classifications
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)


SparkCures Verified

SparkCures is working closely with Arch Oncology to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.

Learn more about how we work with industry partners